{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T05:19:44Z","timestamp":1777526384181,"version":"3.51.4"},"reference-count":28,"publisher":"Elsevier BV","issue":"5","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.ejps.2013.06.005","type":"journal-article","created":{"date-parts":[[2013,6,19]],"date-time":"2013-06-19T15:00:31Z","timestamp":1371654031000},"page":"858-863","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Kinetic and thermodynamic studies of 9-aminocamptothecin hydrolysis at physiological pH in the presence of human serum albumin"],"prefix":"10.1016","volume":"49","author":[{"given":"Deval","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahidur","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michalakis","family":"Savva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2013.06.005_b0005","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s00280-008-0803-x","article-title":"Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of cancer and leukemia group B 9551","volume":"63","author":"Bartlett","year":"2009","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejps.2013.06.005_b0010","first-page":"6318","article-title":"Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin","volume":"49","author":"Bjornsti","year":"1989","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejps.2013.06.005_b0015","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1021\/jm00027a005","article-title":"The structural basis of camptothecin interactions with Human serum albumin: impact of drug stability","volume":"37","author":"Burke","year":"1994","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2013.06.005_b0020","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1006\/abio.1993.1325","article-title":"Preferential binding of the carboxylate form of camptothecin by human serum albumin","volume":"212","author":"Burke","year":"1993","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ejps.2013.06.005_b0025","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1021\/bi00071a010","article-title":"Lipid bilayer partitioning and stability of camptothecin drugs","volume":"32","author":"Burke","year":"1993","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejps.2013.06.005_b0030","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.bbagen.2004.10.013","article-title":"Flavonoid\u2013serum albumin complexation: determination of binding constants and binding sites by fluorescence spectroscopy","volume":"1721","author":"Dufour","year":"2005","journal-title":"Biochim. Biophys. Acta."},{"key":"10.1016\/j.ejps.2013.06.005_b0035","first-page":"641","article-title":"Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins","volume":"8","author":"Garcia-Carbonero","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejps.2013.06.005_b0040","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1093\/nar\/gkq822","article-title":"The geometry of DNA supercoils modulates the DNA cleavage activity of human topoisomerase I","volume":"39","author":"Gentry","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejps.2013.06.005_b0045","doi-asserted-by":"crossref","first-page":"4629","DOI":"10.1021\/bi00437a018","article-title":"On the mechanism of Topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex","volume":"28","author":"Hertzberg","year":"1989","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejps.2013.06.005_b0050","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1200\/JCO.2004.03.016","article-title":"Biweekly 72-h 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York gynecologic oncology group and the Eastern cooperative oncology group","volume":"22","author":"Hochster","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejps.2013.06.005_b0055","first-page":"5077","article-title":"Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin","volume":"49","author":"Hsiang","year":"1989","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejps.2013.06.005_b0060","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/S0006-2952(02)01074-2","article-title":"Predicting plasma protein binding of drugs: a new approach","volume":"64","author":"Kratochwil","year":"2002","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejps.2013.06.005_b0065","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.jct.2008.04.015","article-title":"Kinetic and thermodynamic analysis of 10-hydroxy-camptothecin hydrolysis at physiological pH","volume":"40","author":"Kunadharaju","year":"2008","journal-title":"J. Chem. Therm."},{"key":"10.1016\/j.ejps.2013.06.005_b0070","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00280-003-0657-1","article-title":"A phase I study of 9-aminocamptothecin as a colloidal dispersion formulation given as a fortnightly 72-h infusion","volume":"52","author":"Leguizamo","year":"2003","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejps.2013.06.005_b0075","doi-asserted-by":"crossref","first-page":"10325","DOI":"10.1021\/bi00200a013","article-title":"Differential interactions of camptothecin lactone and carboxylate forms with human blood components","volume":"33","author":"Mi","year":"1994","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejps.2013.06.005_b0080","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ygyno.2004.09.015","article-title":"Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: a gynecologic oncology group study","volume":"96","author":"Miller","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ejps.2013.06.005_b0085","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1021\/cb300648v","article-title":"Drugging topoisomerases: lessons and challenges","volume":"8","author":"Pommier","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejps.2013.06.005_b0090","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1021\/cr900097c","article-title":"DNA Topoisomerase I inhibitors: chemistry, biology and interfacial inhibition","volume":"109","author":"Pommier","year":"2009","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejps.2013.06.005_b0095","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrc1977","article-title":"Topoisomerase I inhibitors: camptothecins and beyond","volume":"6","author":"Pommier","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejps.2013.06.005_b0100","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/kin.20508","article-title":"Kinetic and thermodynamic analysis of 9-nitro-camptothecin hydrolysis at physiological pH in the presence and absence of human serum albumin","volume":"42","author":"Saha","year":"2010","journal-title":"Int. J. Chem. Kinet."},{"key":"10.1016\/j.ejps.2013.06.005_b0105","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.bbagen.2005.06.014","article-title":"Investigation of foscan (R) interactions with plasma proteins","volume":"1725","author":"Sasnouski","year":"2005","journal-title":"Biochim. Biophys. Acta."},{"key":"10.1016\/j.ejps.2013.06.005_b0110","doi-asserted-by":"crossref","first-page":"4379","DOI":"10.1002\/jps.21314","article-title":"Physicochemical characterization and membrane binding properties of camptothecin","volume":"97","author":"Selvi","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2013.06.005_b0115","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2174\/1877946811101020140","article-title":"Thermodynamic studies of SN38 hydrolysis in the presence of human and bovine serum albumin","volume":"1","author":"Sivakumar","year":"2011","journal-title":"Curr. Phys. Chem."},{"key":"10.1016\/j.ejps.2013.06.005_b0120","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/kin.20449","article-title":"Kinetic and thermodynamic characterization of camptothecin hydrolysis at physiological pH in the absence and presence of human serum albumin","volume":"41","author":"Thakur","year":"2009","journal-title":"Int. J. Chem. Kinet."},{"key":"10.1016\/j.ejps.2013.06.005_b0125","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s002800100329","article-title":"A phase I and pharmacologic study of 9-aminocamptothecin administered as a 120-h infusion weekly to adult cancer patients","volume":"48","author":"Thomas","year":"2001","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejps.2013.06.005_b0130","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.2165\/00003495-200262140-00004","article-title":"Camptothecins: a review of their chemotherapeutic potential","volume":"62","author":"Ulukan","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.ejps.2013.06.005_b0135","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1021\/mp900243b","article-title":"Cancer therapies utilizing the camptothecins: a review of the in vivo literature","volume":"7","author":"Venditto","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2013.06.005_b0140","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1021\/jm00161a035","article-title":"Plant antitumor agents. 23. Synthesis and antileukemic activity of camptothecin analogues","volume":"29","author":"Wani","year":"1986","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098713002261?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098713002261?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T01:26:04Z","timestamp":1539566764000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098713002261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S0928098713002261"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2013.06.005","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Kinetic and thermodynamic studies of 9-aminocamptothecin hydrolysis at physiological pH in the presence of human serum albumin","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2013.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}